PillRx only · Granule, For Suspension, Extended Release · Oral
Esomeprazole Magnesium
Esomeprazole Magnesium
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$5.559
Latest avg · Jul 22, 2026
-18%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
5.1K
Rx · 2026 Q1
199K
Units dispensed
-19%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Cipla USA Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Dec 17, 2020RECALLRecall (Class II): Esomeprazole Magnesium for Delayed-Release Oral Suspension 10mg, packaged in unit dose packets, Rx only, Manufactured b…
Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline — Recalling firm: CIPLA — U.S.A. Nationwide